CVS Health (CVS) Stock Forecast & Price Target

Q: What analysts cover CVS Health?

CVS Health has been rated by research analysts at Argus , Bank of America , Barclays , Cantor Fitzgerald , HSBC , JPMorgan Chase & Co. , Mizuho , Piper Sandler , Robert W. Baird , Royal Bank Of Canada , Truist Financial , UBS Group , Weiss Ratings , and Wells Fargo & Company in the past 90 days.

$97.32 +0.12 (+0.12%)

As of 01:36 PM Eastern

Compare

CVS Health - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 24 Analyst Ratings

Sell
0

Hold
2

Buy
22

Based on 24 Wall Street analysts who have issued ratings for CVS Health in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 24 analysts, 2 have given a hold rating, and 22 have given a buy rating for CVS.

Consensus Price Target

$106.83
9.77% Upside

According to the 24 analysts' twelve-month price targets for CVS Health, the average price target is $106.83. The highest price target for CVS is $123.00, while the lowest price target for CVS is $90.00. The average price target represents a forecasted upside of 9.77% from the current price of $97.32.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for CVS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for CVS Health and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVS Analyst Ratings Over Time

Type	Current Forecast 9/4/25 to 9/4/26	1 Month Ago 8/5/25 to 8/5/26	3 Months Ago 6/6/25 to 6/6/26	1 Year Ago 9/4/24 to 9/4/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	22 Buy rating(s)	21 Buy rating(s)	22 Buy rating(s)	17 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	4 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$106.83	$105.67	$99.88	$77.56
Forecasted Upside	9.77% Upside	6.48% Upside	3.93% Upside	5.39% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

CVS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

CVS Health Stock vs. The Competition

Type	CVS Health	Healthcare Companies	Broader Market
Consensus Rating Score	2.92	2.30	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	10.25% Upside	934.34% Upside	14.16% Upside
News Sentiment Rating	Positive News See Recent CVS News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/3/2026	UBS Group 4 of 5 stars	Kevin Caliendo 3 of 5 stars	Lower Target	Buy	$126.00 ➝ $118.00	+22.30%
8/26/2026	Piper Sandler 2 of 5 stars	Jessica Tassan 2 of 5 stars	Reiterated Rating	Overweight
8/19/2026	Argus 3 of 5 stars	Steve Silver Not Rated	Boost Target	Buy	$104.00 ➝ $114.00	+19.92%
8/12/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Gill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$111.00 ➝ $118.00	+26.09%
8/6/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Ha Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$107.00	+10.60%
8/6/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Mok Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$106.00 ➝ $108.00	+8.83%
8/5/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold (C+) ➝ Buy (B-)
7/14/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David MacDonald Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$108.00 ➝ $118.00	+11.26%
7/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Stephen Baxter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$103.00 ➝ $123.00	+18.10%
7/9/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Hendrix Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$107.00 ➝ $113.00	+8.33%
MILLIONAIRE MASTERCLASS INVITE: Altucher (Ad) James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation. Watch James Altucher's free masterclass before September 25
7/7/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$100.00 ➝ $110.00	+7.71%
7/6/2026	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Hold	$103.00	+0.72%
6/22/2026	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allen Lutz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$100.00 ➝ $110.00	+7.54%
6/8/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ann Hynes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$110.00 ➝ $115.00	+20.18%
6/4/2026	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erin Wright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$106.00 ➝ $111.00	+21.17%
5/12/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lance Wilkes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$94.00 ➝ $106.00	+14.89%
5/11/2026	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Charles Rhyee Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$105.00 ➝ $110.00	+20.18%
5/7/2026	DA Davidson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$80.00 ➝ $100.00	+14.05%
5/7/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$88.00 ➝ $92.00	+4.93%
3/5/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Michael Cherny Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$98.00	+23.58%
3/2/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Outperform	$100.00 ➝ $97.00	+20.86%
2/12/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Fidel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$95.00 ➝ $97.00	+23.39%
10/31/2025	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$75.00 ➝ $90.00	+15.20%
10/30/2025	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target		$92.00 ➝ $98.00	+25.44%
10/30/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Elizabeth Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$85.00 ➝ $95.00	+22.55%
9/8/2025	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Strong-Buy ➝ Hold
7/16/2025	Bernstein Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Market Perform	$78.00 ➝ $72.00	+12.86%
1/30/2025	Edward Jones Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold ➝ Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:36 PM ET.

Should I Buy CVS Health Stock? CVS Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 1, 2026. Please send any questions or comments about these CVS Health pros and cons to contact@marketbeat.com.

CVS Health
Bull Case

Here are some ways that investors could benefit from investing in CVS Health Co.:

CVS Health Co. recently demonstrated strong financial performance by reporting earnings per share of $2.58 for the quarter ended August 5, 2026, which significantly exceeded the consensus estimate of $1.87, indicating that the company is generating higher profits than analysts anticipated and potentially signaling a successful operational turnaround.
The stock is currently trading at $97.36, which is below the average analyst price target of $106.75, suggesting that the market may be undervaluing the company relative to Wall Street's expectations for its future growth and profitability.
CVS Health Co. offers a dividend yield of 2.86%, providing investors with a steady stream of income that is higher than many other large-cap healthcare stocks, which can be attractive for income-focused portfolios seeking consistent cash flow.
Recent institutional activity shows significant confidence in the company, with funds like Maple Rock Capital Partners Inc. increasing their holdings by 14.3% and Alyeska Investment Group L.P. acquiring a new stake worth approximately $174.36 million in the second quarter, indicating that professional investors are positioning themselves for potential upside.
The company has a beta of 0.61, which is lower than the market average, meaning CVS Health Co. tends to be less volatile than the broader market, offering a potentially safer investment option for those looking to reduce portfolio risk while still participating in healthcare sector growth.

CVS Health
Bear Case

Investors should be bearish about investing in CVS Health Co. for these reasons:

Despite the recent earnings beat, the stock experienced a gap down of 10.7% on August 5, 2026, falling from a previous close of $104.42 to $98.14, suggesting that some investors may have sold off the stock after the earnings release, possibly due to concerns about sustainability or other undisclosed factors.
CVS Health Co. has a debt-to-equity ratio of 0.74, which indicates a moderate level of leverage, and while not excessively high, it could limit the company's financial flexibility in a rising interest rate environment or during periods of economic uncertainty.
The company's payout ratio is 70.37%, meaning it is distributing a significant portion of its earnings as dividends, which could limit its ability to reinvest in growth initiatives or reduce debt, potentially constraining long-term value creation.
Recent news highlights legal and operational challenges, such as a Milwaukee hospital suing CVS over $18 million in alleged 340B diversion, which could result in financial penalties or reputational damage, adding to the company's risk profile.
While the consensus rating is "Moderate Buy," the average price target of $106.75 is only about 9.7% above the current stock price of $97.36, suggesting limited upside potential compared to other stocks in the healthcare sector that may offer higher growth prospects.

CVS Forecast - Frequently Asked Questions

According to the research reports of 24 Wall Street equities research analysts, the average twelve-month stock price forecast for CVS Health is $106.83, with a high forecast of $123.00 and a low forecast of $90.00.

24 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CVS Health in the last year. There are currently 2 hold ratings and 22 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" CVS shares.

According to analysts, CVS Health's stock has a predicted upside of 9.77% based on their 12-month stock forecasts.

Over the previous 90 days, CVS Health's stock had 2 upgrades by analysts.

CVS Health has been rated by research analysts at Argus, Bank of America, Barclays, Cantor Fitzgerald, HSBC, JPMorgan Chase & Co., Mizuho, Piper Sandler, Robert W. Baird, Royal Bank Of Canada, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like CVS Health more than other "healthcare" companies. The consensus rating for CVS Health is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how CVS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With CVS Health Recommendations

MarketBeat monitors more than a dozen sources for CVS Health analyst ratings, with the most recent rating issued on 9/3/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CVS Health (CVS) Stock Forecast & Price Target